Activated Prothrombin Complex (aPCC) Market Size, Share & Industry Analysis, By Product (FEIBA and Others), By Indication (Hemophilia A and Hemophilia B), By Age Group (Adults and Pediatrics), By Distribution Channel (Specialty Pharmacy, Hospital Pharmacy, and Others), and Regional Forecast, 2026-2034

Region : Global | Report ID: FBI115588 | Status : Ongoing

KEY MARKET INSIGHTS

The activated prothrombin complex (aPCC) market size was valued at USD 280.0 million in 2024 and is projected to reach USD 362.0 million by 2032, exhibiting a CAGR of 3.2% during the forecast period. Activated prothrombin complex is a plasma-derived hemostatic agent containing a mix of vitamin K-dependent clotting factors such as II, VIIa, IX, and X. The market is expected to witness a significant growth trajectory during the forecast period.

Some of the parameters propelling the market include the rising prevalence of hemophilia and increasing demand for bypassing agents to facilitate thrombin generation and clot formation in patients who develop inhibitors against replacement factor therapy.

For instance, as per the Hemophilia Foundation Australia, the prevalence of haemophilia is 1 in 6,000-10,000 of the male population worldwide.

Additionally, the presence of key players in the market with FDA-approved aPCC is expected to further propel the market growth, with a focus on research and development activities.

Activated Prothrombin Complex (aPCC) Market Driver

Rising Prevalence of Inhibitor Development for Hemophilia Patients

The increasing development of inhibitors in hemophilia patients that neutralize the standard factor replacement therapies, increases the demand for aPCC, driving market growth.

For instance, in May 2024, as per the U.S. CDC, approximately 1 in 5 people with hemophilia A and around 3 in 100 people with hemophilia B are expected to develop an inhibitor, an antibody that neutralizes the effects of factor replacement therapy.

Download Free sample to learn more about this report.

According to Haemophilia Foundation Australia, Hemophilia A affects approximately 1 in 6,000 males and Hemophilia B affects about 1 in 26,000 males globally.

Activated Prothrombin Complex (aPCC) Market Restraint

Adverse Reactions Associated with the Complex to Hamper Market Growth

The narrow safety margin hand thromboembolism associated with FEIBA are hampering the greater product adoption and the market growth.

As per the FDA label, thromboembolic events have been reported after the administration of high doses, i.e., 200 units per kg per day, in patients with thrombotic risk factors.

Activated Prothrombin Complex (aPCC) Market Opportunity

R&D Focused on Product Development to Offer New Growth Avenues

The presence of only one FDA-approved aPCC product, FEIBA, is one of the significant opportunities for major pharmaceutical and biotechnology companies to shift their focus on research and development to launch new products in the market.

Segmentation

By Product

By Indication

By Age Group

By Distribution Channel

By Geography

FEIBA
Others

Hemophilia A
Hemophilia B

Adults
Pediatrics

Specialty Pharmacy
Hospital Pharmacy
Others

· North America (U.S. and Canada)

· Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and the Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)

· Latin America (Brazil, Mexico, and the Rest of Latin America)

· Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Key Insights

The report covers the following key insights:

Prevalence of Key Diseases, By Key Countries/ Regions, 2024
Key Industry Developments (Mergers, Acquisitions, Collaborations, and Others)
Regulatory & Reimbursement Scenario, By Key Countries/ Regions
Economic Cost Burden for the Treatment of Key Diseases

Analysis by Product

Based on product, the market is bifurcated into FEIBA and others.

The FEIBA segment dominated the market, being the only approved aPCC product. The dominance of the segment is due to the rising demand for this product globally as inhibitor management protocols are expanding. Furthermore, the strong focus of key players to expand their offerings in the market is expected to boost the segment’s growth.

For instance, in November 2020, Takeda Pharmaceutical Company Limited participated in the American Society of Hematology (ASH) Annual Meeting to showcase its extensive hematology portfolio, including FEIBA.

Analysis by Indication

Based on indication, the market is segmented into Hemophilia A and Hemophilia B.

The hemophilia A segment held a significant share of the market. This is due to the rising prevalence of hemophilia A and the increasing occurrence of inhibitor cases, increasing the demand for the aPCC products.

For instance, as per data published in May 2024, an estimated 33,000 males in the U.S. are suffering from hemophilia.

Analysis by Age Group

The market, in terms of age group, is categorized into adults and pediatrics.

The pediatrics segment held a significant market share. This is particularly due to the increasing diagnoses rates amongst the children and the rate of inhibitor development in infants.

In May 2024, as per data published by the CDC, around 69.7% and 15.6% cases of hemophilia are diagnosed at the age of less than 1 month and 1-6 months old, respectively.

Analysis by Distribution Channel

Based on distribution channel, the market is fragmented into specialty pharmacy, hospital pharmacy, and others.

The specialty pharmacy segment held the maximum market share. The specialty pharmacy is well equipped to handle temperature-sensitive drug products and also offers to facilitate home infusion services. Thus, it is one of the preferred channels to distribute the complex.

For instance, FFF Enterprises, Inc., a specialty pharmacy, is distributing FEIBA in the U.S.

Regional Analysis

Request for Customization to gain extensive market insights.

The market, on the basis of region, has been analyzed across Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a dominant share of the global activated prothrombin complex (aPCC) market in 2024. The presence of advanced facilities for treatment and strong regulatory and reimbursement guidelines bolsters the market growth in the region.

Europe holds a considerable share of the activated prothrombin complex (aPCC) market. The rising prevalence of hemophilia and the presence of adequate healthcare facilities for diagnosis and treatment are expected to propel the regional market growth.

For instance, in 2022/2023, as per the National Institute for Clinical Excellence, U.K., around 9,316 people were diagnosed with haemophilia A

Moreover, the Asia Pacific is expected to grow with a significant CAGR during the forecast period. The increasing demand for aPCC products due to the rising burden of disease in the region is anticipated to boost the market's growth in the region.

Key Players Covered

The global activated prothrombin complex (aPCC) market is highly consolidated, with only one standalone provider.

The report includes the profiles of the following key players:

Takeda Pharmaceutical Company Limited (Japan)

Key Industry Developments

In June 2023, Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) approved FEIBA’s Biologics License Application to increase the infusion rate and reduce the volume of sterile water for reconstitution in adult patients.
In February 2020, Takeda Pharmaceutical Company Limited participated in the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2020, to gather real-world evidence and offer personalized treatment in rare hematology diseases.